Amplia Therapeutics Limited (INNMF) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Melbourne, VIC, Australia. The current CEO is Christopher J. Burns.
INNMF has IPO date of 2021-01-08, listed on the Other OTC, a market capitalization of $47.2M.
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
